Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine and Weekly Docetaxel Followed by Capecitabine Maintenance for Metastatic Breast Cancer
NCT00225056Phase 2Terminated
- Sponsor
- Oncology Specialties
- Start
- Oct 2003
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, docetaxel in breast cancer, sponsored by Oncology Specialties. Started Oct 2003; status: terminated.
02
Drugs
capecitabinedocetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00225056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00225056.